1d
VELO on MSNThis Week in Tech: Vittoria Aero Tires, a Value Gravel Bike with Huge Tire Clearance, and Pas Normal Updates Its KitsThere are always new bike bits, bobs, products, and gear to share. This week in tech news comes all over the spectrum of ...
Just try visiting the San Juan Islands without provoking daydreams of running away to live among the orcas and farmstands.
3d
Cyclingnews on MSNSean Kelly's Classics Column: Tadej Pogačar would be crazy to ride Paris-RoubaixEven after his Strade Bianche victory, it would be crazy for Tadej Pogačar to ride Paris-Roubaix this year.
5d
Irish Examiner on MSNWe tried 2025’s biggest fitness trends from padel to Hyrox – here's what we thoughtFrom reformer pilates to Hyrox, padel, barre and somatic movement - the Irish Examiner's lifestyle team put this year's viral ...
Riders who can't stomach a stream of carbs are getting dropped. The gut is now an essential part of the training plan.
The Scottish Brain Sciences team are on the cusp of medical breakthroughs which will ‘cure’ the world’s most feared disease. They talk to ...
A Bishop McGuinness duo and High Point Central's head coach among NCBCA All-District basketball selections for the 2024-25 ...
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...
"Playing with boys has made me stronger," Janiya Milligan says, and it has given me a tougher mindset as opposed to playing with girls because I’m used to the roughness, ...
Sinn Féin TD Thomas Gould has formally sought an opportunity to address the Dáil in relation to his arrest over an alleged ...
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...
In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results